Всесвітній день боротьби із запальними захворюваннями кишечника
день перший
день другий
Коморбідний ендокринологічний пацієнт
Всесвітній день боротьби із запальними захворюваннями кишечника
день перший
день другий
Коморбідний ендокринологічний пацієнт
Международный эндокринологический журнал 5 (45) 2012
Вернуться к номеру
REVIEW: DPP-4 INHIBITORS ARE LESS EFFECTIVE THAN METFORMIN FOR REDUCING hba1c IN TYPE 2 DIABETES
Авторы: Chatterjee S.
Рубрики: Эндокринология
Разделы: Справочник специалиста
Версия для печати
Question. In adults with type 2 diabetes mellitus, are dipeptidyl peptidase-4 (DPP-4) inhibitors, alone or combined with metformin, effective and safe for glycemic control compared with metformin alone or combined with other hypoglycemic drugs?
Review scope. Included studies compared DPP-4 inhibitors with metformin monotherapy, or DPP-4 inhibitors plus metformin with other hypoglycemic drugs (a sulfonylurea, basal insulin, pioglitazone, or a glucagon-like peptide (GLP)-1 agonist) plus metformin for ≥ 12 weeks in patients > 18 years of age with type 2 diabetes mellitus, and reported glycated hemoglobin (HbA1c) levels. Exclusion criteria were studies of rosiglitazone and hypoglycemic drugs not widely adopted in clinical practice (a-glucosidase inhibitors, glinides, amylin agonists), and pregnancy. Outcomes included changes in HbA1c levels and body weight, and adverse events.
Review methods. MEDLINE, EMBASE/Excerpta Medica, Cochrane Library (all to 2011); conference abstracts from 3 professional associations (2009 and 2010); pharmaceutical company Web sites; ClinicalTrials.gov; and ClinicalStudyResults.org were searched for published and unpublished randomized controlled trials (RCTs). 27 reports of 19 RCTs (n = 13 881) met the selection criteria. 16 reports had adequate randomization, and 10 had adequate allocation concealment. Overall risk for bias for the primary outcome was low in 3 reports, unclear in 9, high in 14, and not assessed in 1.
Main results. DPP-4 inhibitor monotherapy resulted in smaller reductions in HbA1c than did metformin alone or than metformin plus a sulfonylurea or a GLP-1 agonist. DPP-4 inhibitors increased weight compared with metformin alone or metformin plus a GLP-1 agonist but reduced weight compared with metformin plus a sulfonylurea or pioglitazone. DPP-4 inhibitors plus metformin had a lower risk for serious adverse events than did metformin plus pioglitazone (relative risk reduction 53 %, 95% CI 18 to 73) but did not differ from metformin plus a sulfonylurea or GLP-antagonist.
Conclusion. In adults with type 2 diabetes mellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor monotherapy is less effective than metformin monotherapy for reducing HbA1c levels, and DPP-4 inhibitors plus metformin are less effective than metformin plus a sulfonylurea or a GLP-1 agonist. DPP-4 inhibitors vs metformin alone or DPP-4 inhibitors plus metformin vs metformin plus a sulfonylurea, pioglitazone, or a GLP-1 agonist in type 2 diabetes.
Annals of Internal Medicine. — July 2012